Why the study?
Does a 96-hour continuous infusion of Adriamycin achieve comparable cellular concentrations to bolus injection in patients with advanced multiple myeloma?
Does a 96-hour continuous infusion of Adriamycin achieve comparable cellular concentrations to bolus injection in patients with advanced multiple myeloma?
A 96-hour continuous infusion of Adriamycin achieves comparable cellular drug exposure to bolus injection despite lower plasma concentrations, potentially offering a less toxic administration method.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for less toxic continuous Adriamycin infusion; leaves open clinical benefit in advanced multiple myeloma.
Adriamycin (ADM) concentrations in neoplastic plasma cells, nucleated blood cells, bone marrow cells, and plasma were measured in seven patients with advanced multiple myeloma. ADM was administered as a 96-hour infusion of 9 mg/m2/24 hr. Maximum plasma ADM concentrations were 15.8 +/- 4.4 ng/ml. ADM concentrations in nucleated blood cells, bone marrow cells, and plasma cells increased continuously throughout the 96-hour infusion. Maximum cellular levels were up to 200-fold higher than the maximum plasma concentration and were similar to levels observed shortly after administration of the total dose in one rapid injection. The cellular AUC for 96-hour infusion and bolus injection were comparable. Thus continuous infusion is the equivalent of bolus injection in delivering ADM to the target cells in bone marrow, although plasma ADM concentrations remained very low. These results provide support for administering ADM as a continuous infusion with less toxicity and better patient tolerance.
No takes yet. Share an insight, caveat, or question.
Speth et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: